Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Trials Insight: 700028005

Trial Profile

Clinical Trials Insight: 700028005

Phase of Trial: Phase II

Latest Information Update: 06 Dec 2007

At a glance

  • Drugs Omiganan (Primary)
  • Indications Bacterial infections; Rosacea
  • Focus Therapeutic Use
  • Sponsors Cutanea Life Sciences
  • Most Recent Events

    • 06 Dec 2007 The FDA requires that treatment success and the absolute change in the number of inflammatory lesions are considered co-primary endpoints in phase III rosacea trials. Omiganan was associated with significant improvements in these endpoints.
    • 06 Nov 2007 The primary efficacy endpoint not met.
    • 31 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top